Gene-editing, and targeting capabilities of components of gene-editing systems, can be harnessed to provide wide-ranging, practical applications, yet freedom to operate issues often pose ongoing challenges for pioneers and start-ups in this fast-moving, powerful field.
Whilst there is immense focus on CRISPR gene-editing, older techniques continue to have applications, with the early systems providing impetus for further developments in genetic modification in the CRISPR field and beyond.
HGF has one of the most experienced, commercially- minded teams in Europe focussed on gene-editing, with significant experience of involvement in European oppositions affecting the foundational CRISPR IP, as well as advising on and patenting earlier gene-editing systems, such as TALENs.
The core team of specialists that make-up the HGF CRISPR team are backed by a larger group of over 75 patent attorneys and solicitors, with backgrounds in life sciences, pharmaceuticals, chemistry and plant sciences.
Specialising in gene-editing in the context of new human and animal therapies, viral diagnostics, developments in animal farming and microbiome, as well as plant protection and breeding, the HGF CRISPR team includes specialists from the firm’s AgBio team. This enables HGF to develop multidisciplinary IP strategies across this important and complex field.
HGF works with pioneers of CRISPR technology, as well as for clients advancing the field of gene modification and applications of CRISPR, to those that endeavour to resolve important problems, such as antibiotic resistance and infection diagnostics. This wealth of expertise sees HGF attorneys conducting talks at international events and providing articles on IP developments in the fast-evolving CRISPR field, along with the broader genetic engineering sector.
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
World Intellectual Property Day is on 26th April. This year’s theme is IP & SME’s: Taking your ideas to market. World IP day 2021 shines a light on the critical role of …Event details
‘IP & data protection for alternative proteins: how to protect your products in the EU’ webinar will be held on Tuesday 18th May. Join this webinar by BGP, HGF & …Event details